● Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Condition: Epithelial Ovarian Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants1100

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (299)

Research Site	Birmingham, Alabama, United States	Recruiting
Research Site	Little Rock, Arkansas, United States	Not Yet Recruiting
Research Site	La Jolla, California, United States	Not Yet Recruiting
Research Site	Washington D.C., District of Columbia, United States	Recruiting
Research Site	Fort Lauderdale, Florida, United States	Not Yet Recruiting
Research Site	Gainesville, Florida, United States	Recruiting
Research Site	Jupiter, Florida, United States	Recruiting
Research Site	Miami, Florida, United States	Recruiting
Research Site	Weston, Florida, United States	Not Yet Recruiting
Research Site	Chicago, Illinois, United States	Not Yet Recruiting
Research Site	Evanston, Illinois, United States	Not Yet Recruiting
Research Site	Peoria, Illinois, United States	Recruiting

+ 287 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07218809